--- title: "Eikon Therapeutics files for IPO of common stock" url: "https://aibio.space/news/eikon-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-eikn/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-01-09" section: "Financings" tickers: "NASDAQ:EIKN" source: "https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262ds1.htm" summary: "The Delaware company applied to list on the Nasdaq Global Market. The share count and price range are blank in the preliminary prospectus." --- By the aibio.space news desk. Sources - [Eikon Therapeutics, Inc. S-1 (2026-01-09)](https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262ds1.htm) [EIKN](https://aibio.space/companies/eikon-therapeutics/) 2026-01-09 # Eikon Therapeutics files for IPO of common stock, seeks Nasdaq listing as EIKN Tickers [EIKN](https://aibio.space/companies/eikon-therapeutics/) The Delaware company applied to list on the Nasdaq Global Market. The share count and price range are blank in the preliminary prospectus. ## Key facts - **Company**: Eikon Therapeutics, Inc. (NASDAQ: EIKN) - **News type**: Financings - **Primary source**: [Eikon Therapeutics, Inc. S-1 (2026-01-09)](https://www.sec.gov/Archives/edgar/data/1861123/000119312526008888/d903262ds1.htm) *The New York Stock Exchange trading floor. Photo: Carol M. Highsmith, public domain, via Wikimedia Commons. The picture shows the field, not the companies named.* ## The filing and who is named Eikon Therapeutics, Inc. filed a registration statement on Form S-1 on January 9, 2026 for an initial public offering of its common stock. The preliminary prospectus is dated January 9, 2026 and is subject to completion. The number of shares, the price range and the size of the underwriters' option are blank. The company says no public market exists for its common stock before the offering, and it has applied to list on the Nasdaq Global Market under the symbol EIKN. The cover page lists J.P. Morgan, Morgan Stanley, BofA Securities and Cantor as underwriters. The option to buy additional shares runs for 30 days from the prospectus date. The filing lists Covington & Burling LLP and Davis Polk & Wardwell LLP among the counsel copied on the registration statement. It does not say which firm represents the company and which represents the underwriters. The company's agent for service is Roger M. Perlmutter, its chair and chief executive officer. ## The money and the going-concern warning The net loss and comprehensive loss was 243,814 thousand dollars for 2024, as the summary table presents it, against 241,997 thousand for 2023. For the nine months ended September 30, 2025 the net loss was 244,593 thousand dollars, compared with 178,890 thousand for the same nine months of 2024. Research and development expense for the nine months of 2025 was 185,089 thousand dollars. The company has never generated revenue from product sales. The prospectus says the company's recurring losses and financial condition raise substantial doubt about its ability to continue as a going concern. In its interim statements for the nine months ended September 30, 2025, the company says it has capital to fund its plan for about twelve months from the issue date, but that it will need more equity or debt capital for the period after. It says additional capital has not yet been secured. The company also gives a preliminary estimate of cash and cash equivalents of approximately $336.0 million at December 31, 2025, and warns that its year-end closing is not complete and the final figure may differ materially. The dilution is large. The prospectus lists 244,667,649 shares outstanding as of September 30, 2025 after the conversion of 222,658,133 preferred shares into common stock. It also lists 42,509,570 shares issuable on options at a weighted average exercise price of $1.30, 5,515,508 shares issuable on warrants at $5.84, and 10,297,116 shares reserved under the 2019 plan. The prospectus itself says raising additional capital may dilute existing stockholders. ## The science is early The most advanced candidate, EIK1001, is a TLR 7/8 dual-agonist in a global Phase 2/3 registrational trial with pembrolizumab in advanced melanoma. The company says the trial is designed to proceed to completion, subject to an interim analysis by a data monitoring committee. It expects that first interim analysis in the second half of 2026, after which it plans to select the dose. The summary section reports no efficacy results from any trial. A second Phase 2/3 trial of EIK1001 in stage 4 non-small cell lung cancer is in site selection, with about 750 patients planned, and the company expects to dose its first patient in the second half of 2026. The PARP1 candidates EIK1003 and EIK1004 are in Phase 1/2 trials. The company's own rationale is that non-selective PARP inhibitors such as olaparib cause hematologic toxicity, particularly anemia, which has limited their use. That is a reason for the design, not evidence that the candidates are safer. The prospectus also says the track records of Roger M. Perlmutter, its chair and chief executive officer, and Roy Baynes, its chief medical officer, do not guarantee clinical success for any product Eikon develops. The first interim analysis is still ahead, the prospectus carries a going-concern warning, and the stated cash plan covers about twelve months. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story EIKN Eikon Therapeutics, Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/eikon-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-eikn/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Eikon Therapeutics files for IPO of common stock", 2026-01-09, https://aibio.space/news/eikon-therapeutics-files-ipo-common-stock-seeks-nasdaq-listing-eikn/